This question deserves a straight answer, and the straight answer has two parts: what the approved products have shown, and what compounded oral preparations have not.
Key Takeaways
- The approved oral semaglutide product has its own trial programme with its own dose range.
- Oral and injectable doses are not comparable in milligrams, so cross-format dose comparison is meaningless.
- Direct head-to-head trials between oral and injectable formats at matched clinical positions are limited.
- Compounded oral preparations have no published bioavailability or efficacy data of their own.
- Adherence is a real efficacy variable — a format you take consistently outperforms one you skip.
What the approved products establish
Oral semaglutide was developed with an absorption-enhancer formulation and studied in its own trial programme. Those trials established efficacy for that product at its own dose range. Because oral bioavailability is a fraction of subcutaneous, the oral doses studied are numerically much larger than the injectable doses for the same molecule.
The consequence for interpretation: comparing "oral 14 mg" against "injectable 2.4 mg" as though the numbers were on a shared scale produces nonsense. What can be compared is outcomes at each product's own studied doses.
| Claim | Evidence status |
|---|---|
| Approved oral semaglutide produces weight loss | Established in its own trial programme |
| Oral and injectable doses are interchangeable by milligram | False — bioavailability differs substantially |
| Compounded oral preparations match approved oral products | Not established; formulations differ and data is not published |
| Compounded oral preparations match injectables | Not established |
| Adherence affects real-world outcomes | Well established in the general adherence literature |
Where compounded oral sits
This is the part that gets glossed over. A compounded sublingual semaglutide preparation is not the approved oral product. It uses a different formulation, a different route, and it has no published bioavailability data of its own.
Efficacy claims made for compounded oral preparations are therefore borrowed — either from the approved oral product's trials or from the injectable trials. Neither borrowing is supported by data on the specific preparation being sold.
This does not mean compounded oral preparations do not work. It means the evidence base for them is mechanistic reasoning and clinical experience rather than trial data, and you should know which one you are relying on.
MadeMed — Oral Semaglutide
Sublingual- Sublingual format — dissolves under the tongue, no swallowing water required
- Quarterly billing available at a lower effective monthly rate
- Optional membership program discounts refills
Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Compounded GLP-1 medications are prepared by state-licensed pharmacies and are not the same as FDA-approved brand products.
MadeMed — Oral Tirzepatide
Sublingual- Sublingual tirzepatide is still relatively rare — most oral compounding is semaglutide
- Quarterly billing available
- Dose tiers are priced separately; confirm your tier at checkout
Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Compounded GLP-1 medications are prepared by state-licensed pharmacies and are not the same as FDA-approved brand products.
The adherence argument, which is not a consolation prize
Effectiveness in the real world is efficacy multiplied by whether you actually take the thing. The adherence literature is unambiguous that route, frequency and burden affect persistence.
For someone who will not use an injection — because of needle phobia, because of the cold chain, because of travel — an oral format that gets taken consistently is the better treatment regardless of what a trial comparison would show. That is not a weaker argument than an efficacy argument; it is the argument that determines the outcome for that person.
Telos Rx
Flat pricing by plan length- Pricing is flat across dose tiers once your plan length is set
- 12-month plan carries the lowest monthly rate
- Cancel anytime; FSA/HSA accepted
Telos prices by commitment length rather than by milligram, which changes how you should compare it against dose-tiered competitors.
Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Compounded GLP-1 medications are prepared by state-licensed pharmacies and are not the same as FDA-approved brand products.
How to hold the question sensibly
If maximum documented efficacy is your priority and injections are acceptable to you, injectable formats have the largest and most direct evidence base.
If injections are a barrier, oral formats are a real path and the honest framing is that you are trading documented evidence for a treatment you will actually take.
What is not honest is a claim that compounded oral preparations have been shown equivalent to anything. They have not been shown equivalent to anything, because the comparison has not been published.
Frequently Asked Questions
Is oral semaglutide as effective as the injection?
The approved oral and injectable products were studied separately at their own dose ranges. Direct head-to-head comparison at matched clinical positions is limited, and the dose numbers are not comparable.
Do compounded oral preparations have trial data?
No. Efficacy claims for compounded preparations are borrowed from trials of approved products with different formulations.
Why do the oral dose numbers look so much bigger?
Because oral bioavailability is a fraction of subcutaneous. A larger oral dose is required to achieve comparable systemic exposure.
Should I choose injectable if I can tolerate it?
That is a conversation with your prescriber. The injectable evidence base is larger and more direct; whether that outweighs your own practical constraints is individual.